EXAS - Exact Sciences Corporation
| Previous Close | 90.71 |
| Open | 90.87 |
| Bid | 91.50 x 1100 |
| Ask | 91.54 x 1000 |
| Day's Range | 90.10 - 92.45 |
| 52 Week Range | 75.35 - 123.99 |
| Volume | 745,232 |
| Avg. Volume | 2,368,485 |
| Market Cap | 13.456B |
| Beta (5Y Monthly) | 1.35 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.70 |
| Earnings Date | Feb 10, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 123.50 |
- Zacks
Exact Sciences (EXAS) Dips More Than Broader Markets: What You Should Know
Exact Sciences (EXAS) closed the most recent trading day at $87.93, moving -1.83% from the previous trading session.
- PR Newswire
Exact Sciences schedules fourth-quarter, full-year 2019 earnings call
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its fourth-quarter and full-year 2019 financial results after the close of the U.S. financial markets on Feb. 11, 2020. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
- Zacks
Exact Sciences, GameStop, Intel, Intuitive Surgical and Skyworks highlighted as Zacks Bull and Bear of the Day
Exact Sciences, GameStop, Intel, Intuitive Surgical and Skyworks highlighted as Zacks Bull and Bear of the Day
- Zacks
What's in Store for IDEXX Laboratories' (IDXX) Q4 Earnings?
IDEXX's (IDXX) is likely to report strong earnings for Q4, courtesy of a global surge in CAG Diagnostic revenues.
- Zacks
Can Critical Care Aid Edwards Lifesciences (EW) Q4 Earnings?
Robust customer adoption of the HemoSphere all-in-one monitoring platform is likely to have driven Edwards Lifesciences' (EW) Q4 revenues.
- American City Business Journals
Exact Sciences' stock jumps after analysts question competitor's product
Analysts concluded the test results of a competitor did not match the level of detection found in Cologuard, Exact Sciences' stool-based colon cancer test.
- Zacks
Will New Buyouts Aid Quest Diagnostics (DGX) Q4 Earnings?
Quest Diagnostics' (DGX) acquisition of Clinical Laboratory Services of Boston Clinical Laboratories is expected to have been accretive to its Q4 earnings.
- Zacks
Will Segmental Growth Aid Hologic (HOLX) in Q1 Earnings?
Strength in segmental businesses is likely to have aided Hologic's (HOLX) performance in first-quarter fiscal 2020.
- Zacks
What's in Store for Align Technology's (ALGN) Q4 Earnings?
Align Technology (ALGN) is expected to have gained from continued adoption of Invisalign system in Q4.
- TheStreet.com
Exact Sciences Gains After Rival's Colorectal Cancer Screening Product Falls Short
Exact Sciences shares are higher. Analysts who follow the company contend biopsy results presented by Freenome didn't match the detection level of EXAS's Cologuard.
- Simply Wall St.
Is Exact Sciences Corporation (NASDAQ:EXAS) Trading At A 40% Discount?
How far off is Exact Sciences Corporation (NASDAQ:EXAS) from its intrinsic value? Using the most recent financial...
- Zacks
Can Abbott (ABT) Q4 Earnings Ride on Growth in All Lines?
Abbott's (ABT) imminent quarterly results are expected to reflect a solid performance by the Established Pharmaceuticals Division (EPD) business alike the last reported quarter.
- Zacks
Exact Sciences (EXAS) Provides Q4 Expectations, Stock Falls
Exact Sciences (EXAS) revenue growth will likely beat expectations for both the fourth quarter and 2019.
- GuruFocus.com
6 Guru Stocks With Negative Performances
Icahn Enterprises makes the list Continue reading...
- Zacks
Novavax Rises on Fast Track Designation to Influenza Vaccine
The FDA bestows a Fast Track Designation on Novavax's (NVAX) influenza vaccine candidate NanoFlu for adults aged 65 years and older. Shares rally.
- Zacks
Perrigo (PRGO) Rises on Stellar Q419 Preliminary Results
Perrigo (PRGO) announces better-than-expected preliminary results for fourth-quarter 2019 as well as the full year. Shares gain.
- TipRanks
Exact Sciences (EXAS) Stock Has 40% Upside From Here, Says Analyst
Exact Sciences' (EXAS) preliminary quarterly results blew expectations out of the water.Yesterday, the molecular diagnostics company released preliminary results for its fourth quarter that exceeded analysts’ estimates. Total revenue for the quarter is expected to land between $294 million and $296 million, reflecting a top-line beat of about $4 million to $6 million.The better-than-expected outcome was primarily driven by its acquisition of Genomic Health, which was finalized back in November and gave it access to Oncotype DX gene expression tests that have been used in treatment decisions for over 1 million cancer patients globally. During the quarter, Oncotype DX test volume growth of 14%, or total test volume of 41,000, helped Genomic Health generate revenue of between $118 and $119 million, up 13% year-over-year.On top of this, Cologuard, its FDA approved noninvasive, at-home colon cancer screening test, will most likely see revenue come in within the range of $229 million to $230 million. While this falls in line with the consensus estimate, BTIG analyst Amanda Murphy reminds investors that the difference between consensus and guidance is the highest it has been this year. She points out that “consensus for Cologuard revenue was at the high-end of management’s guidance range for the quarter.” If achieved, the figure would also represent a year-over-year increase of 61%.Based on the expected Cologuard revenue, it isn’t surprising to the analyst, then, that volumes for the screening test are also expected to match the estimate. The results indicate Cologuard test volume of 477,000 could be in store. This, however, would not only come in above management’s guidance of between 465,000 to 475,000, but also reflect impressive growth of 63%.While management isn’t offering any 2020 guidance before its earnings call in February, Murphy notes that the results reaffirm her already established bullish thesis. “Since Cologuard was approved in 2014, Exact has secured broad reimbursement coverage, developed a large and experienced sales force, increased its lab capacity to seven million tests per year, and made significant investments in IT infrastructure. We believe Cologuard is currently at an inflection point and expect the company to hit its long-term goal of 40% market penetration by the end of 2030,” she explained. The four-star analyst added, “While not explicitly included in our current valuation model, we are also optimistic around the potential for Exact's liquid biopsy test for liver cancer.”Bearing this in mind, Murphy maintained both a Buy rating as well as a $127 price target. This conveys her confidence in Exact’s ability to climb 40% higher in the next twelve months. (To watch Murphy’s track record, click here)As for the rest of the Street? It turns out that other analysts wholeheartedly agree with the BTIG analyst. Out of 9 total analysts that have published a recommendation over the last three months, 100% see the stock as a Buy. This makes the consensus rating a unanimous Strong Buy. Not to mention the $123.56 average price target puts the upside potential just below Murphy’s forecast at 37%. (See Exact Sciences stock analysis on TipRanks)
- Zacks
Can Focus on High-Growth Area Up OrganiGram (OGI) Q1 Earnings?
OrganiGram (OGI) is expected to have benefited from its firm focus on building brand equity and ongoing product innovation in the fiscal first quarter.
- American City Business Journals
Exact Sciences anticipates 2019 revenue over $876M, more than 1.6M completed Cologuard tests
With the $2.8 billion acquisition deal of California's Genomic Health officially completed, Madison-based Exact Sciences Corp. is calculating the estimated combined revenues earned by both companies for the recent fourth quarter.
- Zacks
Has Exact Sciences (EXAS) Outpaced Other Medical Stocks This Year?
Is (EXAS) Outperforming Other Medical Stocks This Year?
- GuruFocus.com
All 4 of Analysts' Favorite Stocks Fell Last Year
The stocks that Wall Street analysts most adored a year ago all fell Continue reading...
- Zacks
Can New Strategic Efforts Aid Apharia's (APHA) Q2 Earnings?
Apharia (APHA) is successfully running its global cannabis business with more than 1,200 team members globally.
- Zacks
Top Ranked Momentum Stocks to Buy for January 13th
Top Ranked Momentum Stocks to Buy for January 13th
